The management of myelofibrosis: A British Society for Haematology Guideline

This document represents an update of the British Society for Haematology guideline on Myelofibrosis first published in 2012 and updated in 2015. 1 These guidelines aim to provide healthcare professionals with clear guidance on stratified management for primary myelofibrosis (PMF), as well as postpolycythaemia myelofibrosis (post-PV MF) and postessential thrombocythaemia myelofibrosis (post-ET MF).A separate BSH guideline covers the diagnosis and prognostic evaluation of myelofibrosis and is published alongside this guideline. M ETHODOLOGYThese guidelines were compiled according to the BSH process https:// b-s-h.org.uk/ media/ 16732/ bsh-guida nce-devel opmen t-proce ss-dec-5-18.pdf.The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence and assess the strength of recommendations.The GRADE criteria can be found at http:// www.grade worki nggro up.org.Recommendations are based on a review of the relevant myelofibrosis-related literature using Medline, PubMed/Medline and Cochrane searches beginning from 2012 up to mid-2022.Filters were applied to include only publications written in English, studies carried out in humans, clinical conferences, congresses, clinical trials, clinical studies, meta-analyses, multicentre studies and randomised controlled trials.